SCM
RGNX icon

Suvretta Capital Management’s Regenxbio RGNX Stock Holding History

Suvretta Capital Management’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-20,820
Closed -$674K – 100
2020
Q1 		$674K Buy
+20,820
New +$867K 0.02% 56

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Suvretta Capital Management's RGNX Position: Q2 2020 in Review

Suvretta Capital Management sold out of Regenxbio (RGNX) in Q2 2020, closing a stake of 20,820 shares — an estimated $674K sold.

Suvretta Capital Management first reported a position in RGNX in Q1 2020 and held it in 1 quarter. The position peaked at $674K in Q1 2020. 179 funds tracked by Wall St. Rank hold RGNX as of Q2 2020.

  • Suvretta Capital Management reported no remaining Regenxbio position as of Q2 2020 after selling out during the quarter.
  • Suvretta Capital Management sold 20,820 Regenxbio shares in Q2 2020, an estimated $674K.
  • Suvretta Capital Management first reported a position in Regenxbio in Q1 2020 and held it in 1 quarter.
  • Suvretta Capital Management's Regenxbio position peaked at $674K in Q1 2020.
  • 179 funds tracked by Wall St. Rank held Regenxbio as of Q2 2020.

Based on Suvretta Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.